WO2004081021A2 - Oligonucleotide mimetics - Google Patents
Oligonucleotide mimetics Download PDFInfo
- Publication number
- WO2004081021A2 WO2004081021A2 PCT/US2004/007405 US2004007405W WO2004081021A2 WO 2004081021 A2 WO2004081021 A2 WO 2004081021A2 US 2004007405 W US2004007405 W US 2004007405W WO 2004081021 A2 WO2004081021 A2 WO 2004081021A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aptamer
- ctla
- aptamers
- candidate mixture
- del
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title description 8
- 108091023037 Aptamer Proteins 0.000 claims abstract description 216
- 238000000034 method Methods 0.000 claims abstract description 56
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 149
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 134
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 134
- 239000000203 mixture Substances 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 24
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 230000001965 increasing effect Effects 0.000 claims description 18
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 13
- 230000006052 T cell proliferation Effects 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 238000009169 immunotherapy Methods 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 101710163270 Nuclease Proteins 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 5
- 230000036737 immune function Effects 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- -1 4-IBB Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 108091005735 TGF-beta receptors Proteins 0.000 claims description 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 3
- 238000000638 solvent extraction Methods 0.000 claims 2
- 230000033228 biological regulation Effects 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 210000000987 immune system Anatomy 0.000 abstract description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 49
- 230000027455 binding Effects 0.000 description 40
- 238000009739 binding Methods 0.000 description 39
- 230000006870 function Effects 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 22
- 241001529936 Murinae Species 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 238000001727 in vivo Methods 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 17
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 15
- 102000043321 human CTLA4 Human genes 0.000 description 15
- 230000036039 immunity Effects 0.000 description 14
- 108010017842 Telomerase Proteins 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000412 dendrimer Substances 0.000 description 9
- 229920000736 dendritic polymer Polymers 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000001994 activation Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 230000006044 T cell activation Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 150000003212 purines Chemical class 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 108091008103 RNA aptamers Proteins 0.000 description 4
- 101710120037 Toxin CcdB Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108700031895 human F Proteins 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 150000008300 phosphoramidites Chemical class 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 102000053391 human F Human genes 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 241000508725 Elymus repens Species 0.000 description 2
- 108010048049 Factor IXa Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000334993 Parma Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040825 Skin depigmentation Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
- OMAHFYGHUQSIEF-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) oxalate Chemical compound O=C1CCC(=O)N1OC(=O)C(=O)ON1C(=O)CCC1=O OMAHFYGHUQSIEF-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002624 low-dose chemotherapy Methods 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012987 post-synthetic modification Methods 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical class 0.000 description 1
- 125000000548 ribosyl group Chemical class C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 238000012056 up-stream process Methods 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 229940096973 urethral suppository Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04720328A EP1601681A4 (en) | 2003-03-12 | 2004-03-12 | Oligonucleotide mimetics |
AU2004220036A AU2004220036A1 (en) | 2003-03-12 | 2004-03-12 | Oligonucleotide mimetics |
JP2006507070A JP2006522101A (en) | 2003-03-12 | 2004-03-12 | Oligonucleotide analogues |
CA002518782A CA2518782A1 (en) | 2003-03-12 | 2004-03-12 | Oligonucleotide mimetics |
US10/548,532 US20060246123A1 (en) | 2003-03-12 | 2004-03-12 | Oligonucleotide mimetics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45383103P | 2003-03-12 | 2003-03-12 | |
US60/453,831 | 2003-03-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004081021A2 true WO2004081021A2 (en) | 2004-09-23 |
WO2004081021A3 WO2004081021A3 (en) | 2005-06-09 |
Family
ID=32990828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/007405 WO2004081021A2 (en) | 2003-03-12 | 2004-03-12 | Oligonucleotide mimetics |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060246123A1 (en) |
EP (1) | EP1601681A4 (en) |
JP (1) | JP2006522101A (en) |
AU (1) | AU2004220036A1 (en) |
CA (1) | CA2518782A1 (en) |
WO (1) | WO2004081021A2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008048685A2 (en) * | 2006-10-19 | 2008-04-24 | Duke University | Ox40 aptamers |
EP1933850A2 (en) * | 2005-09-15 | 2008-06-25 | Duke University | Aptamers as agonists |
EP1954836A2 (en) * | 2005-11-08 | 2008-08-13 | Avi Biopharma, Inc. | Immunosuppression compound and treatment method |
CN102803961A (en) * | 2009-11-19 | 2012-11-28 | 鳄鱼生物科学公司 | New medical methods and agents for use therein |
US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
WO2017160754A1 (en) | 2016-03-15 | 2017-09-21 | Mersana Therapeutics,Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
WO2018098269A2 (en) | 2016-11-23 | 2018-05-31 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
WO2018160538A1 (en) | 2017-02-28 | 2018-09-07 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
WO2019126691A1 (en) | 2017-12-21 | 2019-06-27 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
US10604574B2 (en) | 2016-06-30 | 2020-03-31 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
WO2020092385A1 (en) | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
WO2021216920A1 (en) | 2020-04-22 | 2021-10-28 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
EP3678708A4 (en) * | 2017-09-08 | 2021-12-08 | Duke University | Nucleolin-targeting aptamers and methods of using the same |
EP4029508A1 (en) | 2014-10-10 | 2022-07-20 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonists and checkpoint inhibitors |
US11634772B2 (en) | 2017-03-23 | 2023-04-25 | Duke University | Antidote-mediated reversal of extracellular aptamer staining |
US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080026947A1 (en) * | 2006-02-08 | 2008-01-31 | Gmeiner William H | Cytotoxic nucleotides for targeted therapeutics |
WO2009045545A2 (en) * | 2007-10-04 | 2009-04-09 | Duke University | Antidotes for agonistic aptamers |
JP5210620B2 (en) * | 2007-12-19 | 2013-06-12 | 独立行政法人科学技術振興機構 | Method and use of peptide aptamer library |
WO2010019446A1 (en) | 2008-08-09 | 2010-02-18 | University Of Iowa Research Foundation | Nucleic acid aptamers |
US9284559B2 (en) | 2009-04-14 | 2016-03-15 | Wake Forest University Health Sciences | Multivalent aptamer complexes |
US20130224237A1 (en) * | 2010-07-20 | 2013-08-29 | University Of Miami | Inhibition of nonsense mediated decay pathways |
WO2012151575A2 (en) | 2011-05-05 | 2012-11-08 | Duke University | A method of controlling coagulation |
EP2734232B1 (en) * | 2011-07-19 | 2017-11-01 | Philogen S.p.A. | Sequential anti-ctla4 and targeted il-2 therapy |
US9486533B2 (en) | 2013-09-27 | 2016-11-08 | Wake Forest University Health Sciences | Pharmaceutical compositions for high-capacity targeted delivery |
US10711272B2 (en) | 2014-01-21 | 2020-07-14 | City Of Hope | CTLA-4 aptamer siRNA species |
EP3174984B1 (en) * | 2014-07-31 | 2020-05-06 | Academia Sinica | Antagonistic ctla-4 aptamers and applications thereof in enhancing immune activity |
BR112021020411A2 (en) * | 2019-04-11 | 2022-03-15 | Univ Arkansas | cd40-specific DNA aptamers as vaccine adjuvants |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
JP2002505673A (en) * | 1997-06-12 | 2002-02-19 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | CD28 / CTLA-4 inhibitory peptidomimetics, their pharmaceutical compositions, and methods of using them |
US6261783B1 (en) * | 1997-12-15 | 2001-07-17 | Gilead Sciences, Inc. | Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction |
US6458559B1 (en) * | 1998-04-22 | 2002-10-01 | Cornell Research Foundation, Inc. | Multivalent RNA aptamers and their expression in multicellular organisms |
JP5341287B2 (en) * | 1998-12-03 | 2013-11-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Stimulation of T cells against self antigens using CTLA-4 blockers |
US20030054360A1 (en) * | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
US6171795B1 (en) * | 1999-07-29 | 2001-01-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to CD40ligand |
AU2002312059B2 (en) * | 2001-05-25 | 2009-01-15 | Duke University | Modulators of pharmacological agents |
JP2006512097A (en) * | 2002-12-23 | 2006-04-13 | シティ・オブ・ホープ | Modified vaccinia / Ankara expressing P53 in cancer immunotherapy |
-
2004
- 2004-03-12 CA CA002518782A patent/CA2518782A1/en not_active Abandoned
- 2004-03-12 JP JP2006507070A patent/JP2006522101A/en active Pending
- 2004-03-12 US US10/548,532 patent/US20060246123A1/en not_active Abandoned
- 2004-03-12 WO PCT/US2004/007405 patent/WO2004081021A2/en active Application Filing
- 2004-03-12 EP EP04720328A patent/EP1601681A4/en not_active Withdrawn
- 2004-03-12 AU AU2004220036A patent/AU2004220036A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of EP1601681A4 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009508491A (en) * | 2005-09-15 | 2009-03-05 | デューク ユニバーシティ | Aptamers as agonists |
EP1933850A2 (en) * | 2005-09-15 | 2008-06-25 | Duke University | Aptamers as agonists |
EP1933850A4 (en) * | 2005-09-15 | 2009-12-23 | Univ Duke | Aptamers as agonists |
EP1954836A4 (en) * | 2005-11-08 | 2010-09-22 | Avi Biopharma Inc | Immunosuppression compound and treatment method |
EP1954836A2 (en) * | 2005-11-08 | 2008-08-13 | Avi Biopharma, Inc. | Immunosuppression compound and treatment method |
US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
US8933216B2 (en) | 2005-11-08 | 2015-01-13 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
US9487786B2 (en) | 2005-11-08 | 2016-11-08 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
WO2008048685A3 (en) * | 2006-10-19 | 2009-04-09 | Univ Duke | Ox40 aptamers |
WO2008048685A2 (en) * | 2006-10-19 | 2008-04-24 | Duke University | Ox40 aptamers |
CN102803961A (en) * | 2009-11-19 | 2012-11-28 | 鳄鱼生物科学公司 | New medical methods and agents for use therein |
EP4029508A1 (en) | 2014-10-10 | 2022-07-20 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonists and checkpoint inhibitors |
WO2017160754A1 (en) | 2016-03-15 | 2017-09-21 | Mersana Therapeutics,Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
EP4302782A2 (en) | 2016-03-15 | 2024-01-10 | Mersana Therapeutics, Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
US11078280B2 (en) | 2016-06-30 | 2021-08-03 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
US10604574B2 (en) | 2016-06-30 | 2020-03-31 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
WO2018098269A2 (en) | 2016-11-23 | 2018-05-31 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
WO2018160538A1 (en) | 2017-02-28 | 2018-09-07 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
US11634772B2 (en) | 2017-03-23 | 2023-04-25 | Duke University | Antidote-mediated reversal of extracellular aptamer staining |
EP3678708A4 (en) * | 2017-09-08 | 2021-12-08 | Duke University | Nucleolin-targeting aptamers and methods of using the same |
US11713464B2 (en) | 2017-09-08 | 2023-08-01 | Duke University | Nucleolin-targeting aptamers and methods of using the same |
WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
WO2019126691A1 (en) | 2017-12-21 | 2019-06-27 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
WO2020092385A1 (en) | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
WO2021216920A1 (en) | 2020-04-22 | 2021-10-28 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
Also Published As
Publication number | Publication date |
---|---|
AU2004220036A1 (en) | 2004-09-23 |
EP1601681A2 (en) | 2005-12-07 |
CA2518782A1 (en) | 2004-09-23 |
WO2004081021A3 (en) | 2005-06-09 |
US20060246123A1 (en) | 2006-11-02 |
JP2006522101A (en) | 2006-09-28 |
EP1601681A4 (en) | 2006-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060246123A1 (en) | Oligonucleotide mimetics | |
EP3356529B1 (en) | Compositions and methods for inhibiting gene expression of lpa | |
CN108064313B (en) | Compositions and methods for inhibiting gene expression of factor XII | |
JP2020534268A (en) | RNAi agents and compositions for inhibiting the expression of angiopoietin-like 3 (ANGPTL3), and methods of use | |
AU777043B2 (en) | Nucleic acid ligands to CD40ligand | |
US20130251736A1 (en) | Methods for reducing granulomatous inflammation | |
KR20200044013A (en) | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | |
EP2111449B1 (en) | H19 silencing nucleic acid agents for treating rheumatoid arthritis | |
TW201639962A (en) | RNA interference agents | |
KR20180104075A (en) | Treatment of atopic dermatitis and asthma using RNA complexes targeting IL4Ra, TRPA1, or F2RL1 | |
JP2002513593A (en) | Antisense modulation of CD40 expression | |
US20230078200A1 (en) | RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION | |
KR20110017005A (en) | Compositions and methods for inhibiting expression of tgf-beta receptor genes | |
US9868776B2 (en) | Anti-sense oligonucleotides targeted against exon 9 of IL-23R-alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases | |
CN111212909A (en) | RNAi agents and compositions for inhibiting expression of asialoglycoprotein receptor 1 | |
Wen et al. | A novel lipopolysaccharide-antagonizing aptamer protects mice against endotoxemia | |
WO2023018523A2 (en) | Products and compositions | |
TW202307207A (en) | Rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use | |
KR20070044813A (en) | Nucleic acid ligands to immunoglobuline e and their use as atopic disease therapeutics | |
JP2023537943A (en) | RNAi constructs and methods for inhibiting MARC1 expression | |
JP2001526521A (en) | Methods and reagents for treating arthritic conditions, inducing graft tolerance and reversing the immune response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004720328 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006507070 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004220036 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2518782 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2004220036 Country of ref document: AU Date of ref document: 20040312 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004220036 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004720328 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006246123 Country of ref document: US Ref document number: 10548532 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10548532 Country of ref document: US |